Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.
OBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range...
| Auteurs principaux: | , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2002
|
| _version_ | 1826273016714100736 |
|---|---|
| author | le Roux, C Jenkins, P Chew, S Camacho-Hübner, C Grossman, AB Besser, G Monson, J |
| author_facet | le Roux, C Jenkins, P Chew, S Camacho-Hübner, C Grossman, AB Besser, G Monson, J |
| author_sort | le Roux, C |
| collection | OXFORD |
| description | OBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range: safety surveillance is therefore mandatory, with particular regard to neoplasia. The aim was to examine whether rhGH replacement in hypopituitary adults is associated with changes in serum prostate-specific antigen (PSA) as a surrogate marker of changes in prostatic growth. DESIGN AND METHODS: A prospective longitudinal study was used with a median follow-up of 22 (range 2.5-32) months, in which 41 men aged over 50 years with adult onset hypopituitarism and GH deficiency during rhGH replacement were examined. Serum PSA and IGF-I were measured at baseline and at latest follow-up. RESULTS: Mean serum PSA remained unchanged during rhGH replacement, with a median follow-up of 2 years. No correlation was found between the individual changes in serum IGF-I and changes in serum PSA. CONCLUSIONS: These data are reassuring thus far regarding the safety of GH replacement in relation to the prostate in this patient group. |
| first_indexed | 2024-03-06T22:21:44Z |
| format | Journal article |
| id | oxford-uuid:55494cd5-521d-44b1-a768-f72c4e2a37e5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:21:44Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:55494cd5-521d-44b1-a768-f72c4e2a37e52022-03-26T16:43:02ZGrowth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:55494cd5-521d-44b1-a768-f72c4e2a37e5EnglishSymplectic Elements at Oxford2002le Roux, CJenkins, PChew, SCamacho-Hübner, CGrossman, ABBesser, GMonson, JOBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range: safety surveillance is therefore mandatory, with particular regard to neoplasia. The aim was to examine whether rhGH replacement in hypopituitary adults is associated with changes in serum prostate-specific antigen (PSA) as a surrogate marker of changes in prostatic growth. DESIGN AND METHODS: A prospective longitudinal study was used with a median follow-up of 22 (range 2.5-32) months, in which 41 men aged over 50 years with adult onset hypopituitarism and GH deficiency during rhGH replacement were examined. Serum PSA and IGF-I were measured at baseline and at latest follow-up. RESULTS: Mean serum PSA remained unchanged during rhGH replacement, with a median follow-up of 2 years. No correlation was found between the individual changes in serum IGF-I and changes in serum PSA. CONCLUSIONS: These data are reassuring thus far regarding the safety of GH replacement in relation to the prostate in this patient group. |
| spellingShingle | le Roux, C Jenkins, P Chew, S Camacho-Hübner, C Grossman, AB Besser, G Monson, J Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. |
| title | Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. |
| title_full | Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. |
| title_fullStr | Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. |
| title_full_unstemmed | Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. |
| title_short | Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years. |
| title_sort | growth hormone replacement does not increase serum prostate specific antigen in hypopituitary men over 50 years |
| work_keys_str_mv | AT lerouxc growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years AT jenkinsp growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years AT chews growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years AT camachohubnerc growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years AT grossmanab growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years AT besserg growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years AT monsonj growthhormonereplacementdoesnotincreaseserumprostatespecificantigeninhypopituitarymenover50years |